Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2002

View Archived Issues

Phase II trials begin in Europe and U.S. for KW-7158

Major European launch for combined oral contraceptive

Data support inhibition of hypocretin system in the treatment of urinary incontinence

Diazepam protects hippocampal neurons from beta-amyloid toxicity

Edema and loss of blood pressure control in elderly hypertensive patients given COX-2 inhibitors

Upregulation of hippocampal and cortical ChAT activity in mild cognitive impairment

Late-stage clinical trial results for new osteoporosis therapy discussed in Lisbon

Buccal heparin completes proof-of-concept study

Roche and Vernalis collaborate on depression and anxiety drug discovery

Oral heparin fails to prove superiority to Lovenox in prevention of DVT

Novel Takeda anticancer agent enters clinical trials

SkyePharma and Kowa strengthen relations

Abgenix discontinues ABX-IL-8 development after disappointing results

Gasmotin launched in third Asian market

Dimethaid completes purchase agreement for Oxo Chemie

Sanochemia and Synaptica collaborate in the field of cognitive disorders

Remitogen enters phase I solid tumor trial

AndroGel approved in Canada for testosterone insufficiency

CYC-202 to be evaluated in glomerulonephritis

Endothelin receptor antagonists identified at Actelion

Boehringer Ingelheim describes new ligands for 5-HT1A, 5-HT2A and/or D4 receptors

Raf kinase inhibitors useful for cancer, neurotraumatic disorders and other conditions

Mercian patents new peptide inhibitors of prolyl endopeptidase and use in dementia

Antiangiogenic tyrosine kinase inhibitors synthesized at Chiron

Novel antiviral agents from Shionogi inhibit HCV RNA-dependent RNA synthase

Tyrosine kinase modulators useful in cancer and other angiogenesis-related conditions

Hisamitsu presents difluoromethylphosphonic acid derivatives for CNS disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...